skip to Main Content
pancreatic cancer researcher Wungki Park, M.D.

Claudin May Be the Next Big Target in Pancreatic Cancer Treatment

While immunotherapy and other targeted treatments involving monoclonal antibodies have been successful in other cancers, pancreatic cancer has been notoriously tough to target because of a lack of suitable cell surface targets to which the antibodies can bind. But a new target has been identified, and researchers are hopeful that an investigational drug that homes…

Dr. Tanios Bekaii-Saab

Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor

That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients. Results of the trial were presented at the 2021 ASCO GI Cancer Symposium. Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2, a vascular…

Marc Binder, a pancreatic cancer survivor, and his wife sit in red Adirondack chairs overlooking water and more land

Another Day to Live

Marc Binder is living with stage IV pancreatic cancer, but he keeps active. Learn more about his approach to treatment and life.

Black and white image of a cancer cell from under a microscope

Immunotherapy for Pancreatic Neuroendocrine Tumors

This trial is active, but no longer recruiting participants. Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs originate in the hormone-making islet cells of the pancreas, respond to different treatments, and have an overall survival rate higher than PDAs. In a clinical trial,…

Back To Top